

Ask the Investigators: Applying Emerging Clinical Research to the Care of Patients with Gastroesophageal Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following adverse events is associated with the anti-HER2 antibody-drug conjugate trastuzumab deruxtecan, which recently received FDA approval based on the results of the DESTINY-Gastric01 trial for patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen?
 - a. QT interval prolongation
 - b. Pneumonitis/interstitial lung disease
 - c. Dysgeusia
2. Which of the following drug types best describes the mechanism of action of bemarituzumab, an investigational agent being studied in combination with modified FOLFOX6 in the ongoing Phase II FIGHT trial for patients with previously untreated unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma?
 - a. PD-1/PD-L1 inhibitor
 - b. Cancer stemness inhibitor
 - c. HER2 inhibitor
 - d. FGFR2b inhibitor
3. The ongoing Phase II/III MOUNTAINEER-02 trial is investigating which agent in combination with trastuzumab, ramucirumab and paclitaxel for patients with previously treated HER2-positive advanced gastric or GEJ adenocarcinoma?
 - a. Tucatinib
 - b. Nivolumab
 - c. Pembrolizumab
 - d. Margetuximab
4. Which of the following anti-PD-1/PD-L1 antibodies recently received FDA approval in combination with platinum and fluoropyrimidine-based chemotherapy for patients with locally advanced or metastatic esophageal or GEJ carcinoma who are not candidates for surgical resection or definitive chemoradiation therapy?
 - a. Margetuximab only
 - b. Durvalumab only
 - c. Pembrolizumab only
 - d. Margetuximab, durvalumab and pembrolizumab